论文部分内容阅读
目的观察羟基脲联合小剂量阿糖胞苷治疗慢性粒细胞白血病慢性期的临床疗效。方法将30例慢性粒细胞白血病患者随机分为治疗组和对照组各15例。2组均给予羟基脲治疗,治疗组同时给予小剂量阿糖胞苷治疗。比较2组临床疗效和不良反应。结果治疗组达完全血液学缓解13例(86.7%),所需时间为11~42d,无病生存期时间为(18.9~61.2)个月;对照组达完全血液学缓解6例(40.0%),所需时间为27~66d,无病生存期时间为(8.9~30.5)个月;2组比较差异有统计学意义(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论联合应用小剂量阿糖胞苷治疗慢性粒细胞白血病可取的较好疗效,值得临床推广应用。
Objective To observe the clinical efficacy of hydroxyurea combined with low dose of cytarabine in the treatment of chronic myeloid leukemia in chronic phase. Methods Thirty patients with chronic myeloid leukemia were randomly divided into treatment group and control group, 15 cases each. Both groups were given hydroxyurea treatment, the treatment group also given a small dose of cytarabine treatment. The clinical efficacy and adverse reactions in two groups were compared. Results In the treatment group, complete hematological response was achieved in 13 cases (86.7%), the required time was 11-42 days, and the disease-free survival time was (18.9-61.2) months. The control group achieved complete hematological response in 6 cases (40.0% , The required time was 27 ~ 66d, disease-free survival time was (8.9 ~ 30.5) months; There was significant difference between the two groups (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combined application of small doses of cytarabine in the treatment of chronic myeloid leukemia is preferable to the curative effect, worthy of clinical application.